Xeris Biopharma Holdings, Inc./$XERS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
- Ticker
- $XERS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 435
- Headquarters
- Chicago, United States
- Website
- www.xerispharma.com
XERS Metrics
BasicAdvanced
$2B
-
-$0.10
0.85
-
Price and volume
Market cap
$2B
Beta
0.85
52-week high
$11.42
52-week low
$5.25
Average daily volume
2.9M
Financial strength
Current ratio
1.449
Quick ratio
0.949
Long term debt to equity
-22.534
Total debt to equity
-29.735
Interest coverage (TTM)
0.85%
Profitability
EBITDA (TTM)
48.769
Gross margin (TTM)
86.58%
Net profit margin (TTM)
-5.12%
Operating margin (TTM)
10.91%
Revenue per employee (TTM)
$770,000
Management effectiveness
Return on assets (TTM)
6.13%
Return on equity (TTM)
118.22%
Valuation
Price to revenue (TTM)
5.373
Price to book
-191
Price to tangible book (TTM)
-16.94
Price to free cash flow (TTM)
32.374
Free cash flow yield (TTM)
3.09%
Free cash flow per share (TTM)
0.331
Growth
Revenue change (TTM)
36.33%
Earnings per share change (TTM)
-51.36%
3-year revenue growth (CAGR)
35.75%
3-year earnings per share growth (CAGR)
-42.00%
What the Analysts think about XERS
Analyst ratings (Buy, Hold, Sell) for Xeris Biopharma Holdings, Inc. stock.
Analyst projections of the future price of Xeris Biopharma Holdings, Inc. stock.
Bulls say / Bears say
Xeris’s commercial growth is accelerating, led by Recorlev: second-quarter product revenue rose 34% year on year and Recorlev sales climbed 81%. The company raised its full-year revenue guidance to $385–390 million. (SEC)
The business is generating stronger operating cash flow: Xeris reported $18.1 million of cash from operations in the first half, versus using $9.8 million a year earlier, and adjusted EBITDA rose to $34.4 million. That gives it more capacity to fund commercial growth and development internally. (SEC, SEC)
XP-8121 could add a sizeable growth opportunity: Xeris plans a Phase 3 programme for its once-weekly injected levothyroxine, aimed in part at patients whose thyroid levels remain poorly controlled on oral treatment. The company has outlined a large clinical programme and a potential 2030 launch, although success is not assured. (SEC, Seeking Alpha)
Recorlev’s patent protection is being challenged by several generic-drug applicants that have filed applications seeking approval to sell copies. If those challenges ultimately succeed, competition could threaten the product that is currently driving most of Xeris’s growth. (SEC)
Growth is uneven across the portfolio: second-quarter Gvoke revenue fell 4% year on year, while Keveyis grew only 2%. That leaves the near-term growth story heavily reliant on Recorlev continuing its rapid expansion. (SEC)
The company is spending more to expand its sales force and advance its pipeline: second-quarter SG&A rose 37% and research and development costs rose 32% year on year. Xeris also had about $253 million of debt at June-end, so sustained investment and borrowing costs could weigh on profits if sales growth slows. (SEC, SEC)
Data summarised monthly by Lightyear AI. Last updated on 27 Oct 2026.
XERS Financial Performance
Revenues and expenses
XERS Earnings Performance
Company profitability
Upcoming events
No upcoming events
XERS News
AllArticlesVideos
Funds containing XERS
Fund name | Fund size | $XERS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.12% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.12% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.06% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.06% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.